Glioma targeting and anti-glioma effect of interleukin 13 peptide and RGD peptide dual functionalized nanoparticles

Current Pharmaceutical Biotechnology

Volumn 14, Issue 13, 2014, Pages 1118-1126

  Gao, Huile ^a,b   Hu, Yue ^c   Xiong, Yang ^a   Zhang, Shuang ^a   Yang, Jiarong ^c   Yu, Lian ^c   Jiang, Xinguo ^a  

^a FUDAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

^c JIAMUSI UNIVERSITY   (China)

Author keywords

Dual targeting; Glioma; Interleukin 13 peptide; Nanoparticles; RGD

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; DOCETAXEL; INTERLEUKIN 13; NANOPARTICLE; ANTINEOPLASTIC AGENT; ARGINYL-GLYCYL-ASPARTIC ACID; COUMARIN 6; COUMARIN DERIVATIVE; FLUORESCENT DYE; OLIGOPEPTIDE; THIAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG RELEASE; GLIOMA; IN VITRO STUDY; MALE; MOUSE; NICK END LABELING; NONHUMAN; QUANTITATIVE ANALYSIS; ANIMAL; BAGG ALBINO MOUSE; CELL SURVIVAL; DRUG EFFECTS; METABOLISM; PARTICLE SIZE; PROCEDURES;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL SURVIVAL; COUMARINS; DRUG DELIVERY SYSTEMS; FLUORESCENT DYES; GLIOMA; INTERLEUKIN-13; MALE; MICE; MICE, INBRED BALB C; NANOPARTICLES; OLIGOPEPTIDES; PARTICLE SIZE; THIAZOLES;

EID: 84903718955     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/1389201015666140425102937     Document Type: Article

References (36)

1. Peer, D.; Karp, J.M.; Hong, S.; Farokhzad, O.C.; Margalit, R.; Langer, R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol., 2007, 2, 751-760.
2. Brannon-Peppas, L.; Blanchette, J.O. Nanoparticle and targeted systems for cancer therapy. Adv. Drug. Deliv. Rev., 2004, 56, 1649-1659.
3. Davis, M.E.; Chen, Z.G.; Shin, D.M. Nanoparticle therapeutics: An emerging treatment modality for cancer. Nat. Rev. Drug. Discov., 2008, 7, 771-872.
4. Matsumura, Y.; Maeda, H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res., 1986, 46, 6387-6392.
5. Maeda, H.; Nakamura, H.; Fang, J. The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv. Drug Deliv. Rev., 2013, 65, 71-79.
6. Barenholz, Y. C. Doxil(R) - The first FDA-approved nano-drug: Lessons learned. J. Control Release, 2012, 160, 117-134.
7. Fu, Q.; Sun, J.; Zhang, W.; Sui, X.; Yan, Z.; He, Z. Nanoparticle albumin-bound (NAB) technology is a promising method for anticancer drug delivery. Rec. Pat. Anticancer Drug Discov., 2009, 4, 262-272.
8. Gao, H.; Wang, Y.; Chen, C.; Chen, J.; We, Y.; Cao, S.; Jiang, X. Incorporation of lapatinib into core-shell nanoparticles improves both the solubility and anti-glioma effects of the drug. Int. J. Pharm., 2014, 461, 478-488.
9. Zhou, J.; Zhang, X.; Li, M.; Wu, W.; Sun, X.; Zhang, L.; Gong, T. Novel lipid hybrid albumin nanoparticle greatly lowered toxicity of pirarubicin. Mol. Pharm., 2013, 10, 3832-3841.
10. Allen, T.M.; Cullis, P.R. Liposomal drug delivery systems: from concept to clinical applications. Adv. Drug Deliv. Rev., 2013, 65, 36-48.
11. Gao, H.; Pang, Z.; Jiang, X. Targeted delivery of nano-therapeutics for major disorders of the central nervous system. Pharm. Res., 2013, 30, 2485-2498.
12. Florence, A.T. Targeting nanoparticles: The constraints of physical laws and physical barriers. J. Control Release, 2012, 164, 115-124.
13. Bae, Y.H.; Park, K. Targeted drug delivery to tumors: myths, reality and possibility. J. Control Release, 2011, 153, 198-205.
14. van der Meel, R.; Vehmeijer, L.J.; Kok, R.J.; Storm, G.; van Gaal, E.V. Ligand-targeted particulate nanomedicines undergoing clinical evaluation: Current status. Adv. Drug Deliv. Rev., 2013, 65, 1284-1298.
15. Nagane, M.; Pan, G.; Weddle, J.J.; Dixit, V.M.; Cavenee, W.K.; Huang, H.J. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Res., 2000, 60, 847-853.
16. Gao, H.; Qian, J.; Cao, S.; Yang, Z.; Pang, Z.; Pan, S.; Fan, L.; Xi, Z.; Jiang, X.; Zhang, Q. Precise glioma targeting of and penetration by aptamer and peptide dual-functioned nanoparticles. Biomaterials, 2012, 33, 5115-5123.
17. Gao, H.; Xiong, Y.; Zhang, S.; Yang, Z.; Cao, S.; Jiang, X.RGD and Interleukin-13 peptide functionalized nanoparticles for enhanced glioblastoma cells and neovasculature dual targeting delivery and elevated tumor penetration. Molecular Pharmaceut., 2014, 11, 1042-1052.
18. Gao, H.; Yang, Z.; Cao, S.; Xiong, Y.; Zhang, S.; Pang, Z.; Jiang, X. Tumor cells and neovasculature dual targeting delivery for glioblastoma treatment. Biomaterials, 2014, 35, 2374-2382.
19. Kawakami, M.; Leland, P.; Kawakami, K.; Puri, R. K. Mutation and functional analysis of IL-13 receptors in human malignant glioma cells. Oncol Res., 2001, 12, 459-467.
20. Mintz, A.; Gibo, D. M.; Slagle-Webb, B.; Christensen, N. D.; Debinski, W. IL-13Ralpha2 is a glioma-restricted receptor for interleukin- 13. Neoplasia, 2002, 4, 388-399.
21. Gao, H.; Yang, Z.; Zhang, S.; Cao, S.; Shen, S.; Pang, Z.; Jiang, X. Ligand modified nanoparticles increases cell uptake, alters endocytosis and elevates glioma distribution and internalization. Sci. Rep., 2013, 3, 2534.
22. Bello, L.; Francolini, M.; Marthyn, P.; Zhang, J.; Carroll, R.S.; Nikas, D.C.; Strasser, J.F.; Villani, R.; Cheresh, D.A.; Black, P.M. Alpha(v)beta3 and alpha(v)beta5 integrin expression in glioma periphery. Neurosurgery, 2001, 49, 380-9; discussion 390.
23. Ruoslahti, E.; Pierschbacher, M.D. New perspectives in cell adhesion: RGD and integrins. Science, 1987, 238, 491-497.
24. Trudeau, M.E. Docetaxel: A review of its pharmacology and clinical activity. Can. J. Oncol., 1996, 6, 443-457.
25. Lyseng-Williamson, K.A.; Fenton, C. Docetaxel: A review of its use in metastatic breast cancer. Drugs, 2005, 65, 2513-2531.
26. Sampath, P.; Rhines, L.D.; DiMeco, F.; Tyler, B.M.; Park, M.C.; Brem, H. Interstitial docetaxel (taxotere), carmustine and combined interstitial therapy: A novel treatment for experimental malignant glioma. J. Neurooncol., 2006, 80, 9-17.
27. Kemper, E.M.; Verheij, M.; Boogerd, W.; Beijnen, J.H.; van Tellingen, O. Improved penetration of docetaxel into the brain by co-administration of inhibitors of P-glycoprotein. Eur. J. Cancer, 2004, 40, 1269-1274.
28. Gao, H.; Pan, S.; Yang, Z.; Cao, S.; Chen, C.; Jiang, X.; Shen, S.; Pang, Z.; Hu, Y. A cascade targeting strategy for brain neuroglial cells employing nanoparticles modified with angiopep-2 peptide and EGFP-EGF1 protein. Biomaterials, 2011, 32, 8669-8675.
29. Gao, H.; Pang, Z.; Fan, L.; Hu, K.; Wu, B.; Jiang, X. Effect of lactoferrin- and transferrin-conjugated polymersomes in brain targeting: in vitro and in vivo evaluations. Acta Pharmacol. Sin., 2010, 31, 237-243.
30. Gao, H.; Pang, Z.; Pan, S.; Cao, S.; Yang, Z.; Chen, C.; Jiang, X. Anti-glioma effect and safety of docetaxel-loaded nanoemulsion. Arch Pharm. Res., 2012, 35, 333-341.
31. Hobbs, S.K.; Monsky, W.L.; Yuan, F.; Roberts, W.G.; Griffith, L.; Torchilin, V.P.; Jain, R.K. Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment. Proc. Natl. Acad. Sci. USA, 1998, 95, 4607-4612.
32. Sarin, H.; Kanevsky, A.S.; Wu, H.; Brimacombe, K.R.; Fung, S.H.; Sousa, A.A.; Auh, S.; Wilson, C.M.; Sharma, K.; Aronova, M.A.; Leapman, R.D.; Griffiths, G.L.; Hall, M.D. Effective transvascular delivery of nanoparticles across the blood-brain tumor barrier into malignant glioma cells. J. Transl. Med., 2008, 6, 80.
33. Gao, H.; Qian, J.; Yang, Z.; Pang, Z.; Xi, Z.; Cao, S.; Wang, Y.; Pan, S.; Zhang, S.; Wang, W.; Jiang, X.; Zhang, Q. Whole-cell SELEX aptamer-functionalised poly(ethyleneglycol)-poly(epsiloncaprolactone) nanoparticles for enhanced targeted glioblastoma therapy. Biomaterials, 2012, 33, 6264-6272.
34. Ganta, S.; Devalapally, H.; Shahiwala, A.; Amiji, M. A review of stimuli-responsive nanocarriers for drug and gene delivery. J. Control Release, 2008, 126, 187-204.
35. Li, Y.; He, H.; Jia, X.; Lu, W. L.; Lou, J.; Wei, Y. A dual-targeting nanocarrier based on poly(amidoamine) dendrimers conjugated with transferrin and tamoxifen for treating brain gliomas. Biomaterials, 2012, 33, 3899-3908.
36. Tang, J.; Zhang, L.; Liu, Y.; Zhang, Q.; Qin, Y.; Yin, Y.; Yuan, W.; Yang, Y.; Xie, Y.; Zhang, Z.; He, Q. Synergistic targeted delivery of payload into tumor cells by dual-ligand liposomes comodified with cholesterol anchored transferrin and TAT. Int. J. Pharm., 2013, 454, 31-40.